RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations
Version of Record online: 27 MAR 2012
© 2012 The Authors. Pathology International © 2012 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd
Volume 62, Issue 5, pages 324–330, May 2012
How to Cite
Iwakoshi, A., Murakumo, Y., Kato, T., Kitamura, A., Mii, S., Saito, S., Yatabe, Y. and Takahashi, M. (2012), RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations. Pathology International, 62: 324–330. doi: 10.1111/j.1440-1827.2012.02797.x
- Issue online: 24 APR 2012
- Version of Record online: 27 MAR 2012
- Received 8 November 2011. Accepted for publication 14 January 2012.
- epidermal growth factor receptor mutation;
- lung cancer;
- RET finger protein;
- thyroid transcription factor 1
The RET finger protein (RFP) is a transcription factor belonging to the TRIM (tripartite motif) superfamily of proteins. RFP is expressed in a variety of human and rodent tumor cell lines and in several kinds of human cancer. Expression of RFP is associated with prognosis of colon and endometrial cancers. In the present study, we evaluated the expression of RFP in lung cancer and assessed its clinical significance. Tissue microarrays were constructed from 108 cases of lung cancer, and the sections were analyzed for RFP expression by immunohistochemistry. RFP expression was detected in the nucleus in 66.7% of lung cancer tissues examined. RFP expression was statistically significantly associated with thyroid transcription factor 1 (TTF-1) expression (P= 0.028). However, no significant association was observed between RFP expression and other clinicopathological or genetic factors, including epidermal growth factor receptor (EGFR) mutations. Interestingly, we found that RFP expression correlated with poor prognosis in patients with EGFR mutations (P= 0.032). Our results suggest that RFP has a role in mutated EGFR signaling and that RFP status may be a prognostic factor for lung cancer with EGFR mutations.